Extranodal marginal zone B-cell lymphoma (MALT type)

Clinical trials for Extranodal marginal zone B-cell lymphoma (MALT type)

4 trials across Europe

See all trials →

Quick filters

4 Clinical trials

Marginal zone lymphoma+3

Recruiting

Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

Registered drugNo placebo

Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Marginal zone lymphoma+3

Not recruiting

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

Registered drugNo placebo

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Nodal marginal zone B-cell lymphoma+2

Not recruiting

Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

Registered drugNo placebo

Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Extranodal marginal zone B-cell lymphoma (MALT type)

Not recruiting

Study on Chlorambucil and Rituximab for Patients with MALT Lymphoma

Registered drugNo placebo

Study on Chlorambucil and Rituximab for Patients with MALT Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Chlorambucil
Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)